Prognostic implications of dual tracer PET/CT: PSMA ligand and [\(^{18}\text{F}\)] FDG PET/CT in patients undergoing [\(^{177}\text{Lu}\)]PSMA radioligand therapy

Kerstin Michalski\(^1\) · Juri Ruf\(^1\) · Christian Goetz\(^1\) · Anna Katharina Seitz\(^2\) · Andreas K. Buck\(^3\) · Constantin Lapa\(^4\) · Philipp E. Hartrampf\(^3\)

Received: 28 August 2020 / Accepted: 8 December 2020 / Published online: 18 December 2020
© The Author(s) 2020

Abstract

**Background** Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with \(^{177}\text{Lu}\)-labeled PSMA ligands has achieved remarkable results in advanced disease stages of metastatic castration-resistant prostate cancer (mCRPC). However, not all patients benefit from this therapy. Different treatment responses could be explained by tumor heterogeneity triggered by progression and the number of prior treatments. PSMA-negative lesions can be missed on PSMA ligand PET/CT, which subsequently results in an underestimation of tumor burden. Conversely, high FDG uptake may also be an indicator of tumor aggressiveness and thus a poor prognostic marker for response to RLT and overall survival (OS). The aim of this analysis was to investigate the prognostic value of combined PSMA ligand PET/CT and \([^{18}\text{F}]\)fluorodeoxyglucose (FDG) PET/CT for outcome prediction in patients undergoing RLT.

**Materials and methods** This bicentric analysis included 54 patients with mCRPC who underwent both FDG and PSMA ligand PET/CT imaging before RLT. In all patients, the pattern of PSMA ligand and FDG uptake was visually assessed. Patients with at least one FDG-positive, but PSMA-negative (FDG+/PSMA\(^{-}\)) lesions were compared to patients without any FDG+/PSMA\(^{-}\}lesions. A log-rank analysis was used to assess the difference in OS between subgroups.

**Results** Median OS was 11 ± 1.8 months (95% CI 7.4–14.6). A significantly lower OS \((p<0.001)\) was found in patients with at least one FDG+/PSMA\(^{-}\}lesion at baseline PET/CTs \((n=18)\) with a median OS of 6.0 ± 0.5 months (95% CI: 5.0–7.0 months). In comparison, patients without any FDG+/PSMA\(^{-}\}lesions \((n=36)\) had a median OS of 16.0 ± 2.5 months (95% CI: 11.2–20.8 months).

**Conclusion** FDG+/PSMA\(^{-}\}lesions are a negative predictor of overall survival in patients with mCRPC undergoing RLT. However, it remains to be determined if patients with FDG+/PSMA\(^{-}\}lesions should be excluded from PSMA RLT.

**Keywords** PSMA · FDG · PET/CT · Prostate cancer · Radioligand therapy
**Introduction**

In advanced prostate cancer, tumor progression under androgen deprivation marks the transition from a hormone-sensitive to a castration-resistant stage of disease [1]. In metastatic castration-resistant prostate cancer (mCRPC), several classes of medical treatment have successfully prolonged survival, including next-generation androgen receptor signaling inhibitors such as abiraterone and enzalutamide [2, 3], or chemotherapy with docetaxel and cabazitaxel [4] [5] [6]. Additionally, prostate-specific membrane antigen- (PSMA) targeted radioligand therapy (RLT) with [177Lu]-labeled PSMA-ligands has achieved remarkable results in advanced disease stages [7]. The most important selection criterion for RLT is a high expression of PSMA of the tumor as assessed by adequate tracer uptake on PSMA ligand PET/CT [8]. Nevertheless, the patient group scheduled for PSMA-directed RLT is most likely heterogeneous both in terms of prior treatment as well as in terms of tumor biology. Parameters which may help in predicting and optimizing response rates to RLT are under investigation, such as additional assessment of tracer uptake on [18F]fluorodeoxyglucose (FDG) PET/CT that appears to be useful for the detection of more aggressive disease [9, 10]. In line with this, the semiquantitative measurement of FDG uptake at baseline FDG PET/CT appears to deliver independent prognostic information on overall survival (OS) in mCRPC [11]. In patients undergoing RLT with [177Lu]Lu-PSMA 617, a high baseline FDG uptake was associated with higher Gleason scores and poorer progression-free survival [12]. As tumor PSMA expression can decrease or get lost during several lines of treatment, additional FDG PET/CT scanning may play an important role in the detection of such lesions [13] [14]. Lesions showing increased FDG-uptake but no relevant uptake on PSMA ligand PET (FDG+/PSMA−) have been used as an exclusion criterion prior to PSMA RLT in a recent single-centre, single-arm phase 2 study with [177Lu]Lu-PSMA 617 therapy in patients with mCRPC (LuPSMA Trial) [14]. Whereas encouraging results could be shown for patients receiving RLT [14, 15], the subjects excluded from the trial due to FDG+/PSMA− lesions had a very poor OS under standard of care [16].

The aim of this bi-centric retrospective study was to evaluate the rate of FDG+/PSMA− lesions on PSMA ligand and FDG PET/CT in patients undergoing RLT and their prognostic implications. Therefore, dual FDG and PSMA ligand PET/CT scans before RLT were analyzed and the results correlated to OS.

**Patients and methods**

**Patient cohort**

Searching the databases of the University Hospital Würzburg for the period between December 2018 and February 2020 and that of the University Hospital Freiburg for the period between August 2018 and December 2019, all consecutive patients who underwent at least one cycle of RLT as systemic treatment for mCRPC were identified. PSMA ligand PET/CT was performed to assess eligibility for PSMA-directed RLT. In case of adequate PSMA expression, the patients routinely underwent a subsequent FDG PET/CT scan to assess the presence of PSMA-negative metastases. In case of PSMA-negative metastases, PSMA RLT was only offered if the majority of metastases was PSMA-positive, and if PSMA RLT was the last therapeutic option.

Time intervals between PET/CT scans and first administration of RLT were as follows: PSMA ligand PET/CT and FDG PET/CT 24.9 ± 18.0 days (range: 1–68); PSMA ligand PET/CT and first cycle of RLT 35.6 ± 20.9 days (range: 2–85).

The study was approved by the local ethics committees (Freiburg: protocol no. 251/17; Würzburg: protocol no. 20190815 01).

**Imaging and treatment protocol**

Whole-body PET scans were acquired using a PET/CT scanner with either full-dose contrast-enhanced diagnostic CT (PSMA ligand) or low-dose CT (FDG) for attenuation correction and anatomical co-registration. Both PET/CT studies were performed on two separate days. A detailed description of the imaging protocols can be found in the supplementary material. Standardized institutional protocols for RLT work-up were applied. In-house labeling was carried out for [177Lu]-labeled PSMA ligands ([177Lu]Lu-PSMA I&T (Würzburg), and [177Lu]Lu-PSMA 617 (Freiburg), which are considered comparable in their efficacy [8]. The standard PSMA RLT protocol consisted of infusion of 6.0 GBq of the radioligand every 6–8 weeks with up to 4 cycles depending on response to treatment.

**Image analysis**

PET/CT images were retrospectively analyzed using commercial software packages (Würzburg: Syngo.via; VB30A, Siemens Healthcare, Erlangen, Germany; Freiburg: IMPAX EE; Agfa Health Care, Bonn, Germany). All lesions with non-physiological, higher uptake of the PSMA ligand or FDG than the physiological background were rated as PSMA− or FDG-positive, respectively. No size threshold was defined for positive lesions. Images were visually evaluated independently by two nuclear medicine specialists with at least 1-year experience in PET/CT reading using two categories: presence of one or more discordant lesions (FDG-positive but PSMA-negative) or absence of discordant FDG+/PSMA− lesions. These visual categories were established and validated in Freiburg by two readers (KM and CG) using the first 10 included patients. Interobserver agreement in the training phase was substantial, as indicated by Cohens κ = 0.78, based on
Landis and Koch criteria [17]. Figure 1 gives examples of the categories. Furthermore, the number of discordant lesions was noted (1 lesion, ≤ 3 lesions, or ≥ 4 lesions). The extent of metastases on PSMA ligand PET/CT was classified following the PROMISE Classification [18] with modifications: low tumor burden (≤ 3 metastases), intermediate tumor burden (> 3 but < 10 metastases), high tumor burden (≥ 10 metastases), and diffuse bone marrow involvement.

Statistical analysis

Statistical analyses were performed using SPSS software ver. 26.0 (IBM, Armonk, NY, USA). Descriptive data are presented as mean ± standard deviation and range. Survival data are analyzed by Kaplan-Meier curves and log-rank comparison. Univariate Cox regression for continuous variables was applied. Multivariable analysis was undertaken for stratification of probable prognostic markers. OS was calculated starting with the first cycle of RLT and is presented as median ± standard error and 95% confidence interval [CI]. For statistical comparison between subgroups, an unpaired *t* test was performed. A *p* value less than 0.05 was considered statistically significant.

Results

Patients’ characteristics

Fifty-four patients (Würzburg: *n* = 26; Freiburg: *n* = 28) who underwent dual tracer PET/CT before at least one cycle of PSMA-targeted RLT were included in this analysis. Detailed characteristics of all included patients are given in Table 1. Mean patient age was 71.4 ± 8.5 years (range: 52–90). Mean time interval since initial diagnosis of prostate cancer and imaging was 7.7 ± 5.6 years (range: 1.7–26.3) and median initial Gleason score was 8 (range: 5–10, *n* = 48; unknown in six patients). Performance status according to Eastern Cooperative Oncology Group (ECOG) ranged from 0 to 3 (0: 52%; 1: 37%; 2: 9%; 3: 2%). Almost all patients (*n* = 52/96%) presented with bone metastases. Other frequent sites of metastatic spread included lymph nodes (*n* = 33, 61%), the liver (*n* = 13, 24%), and the lungs (*n* = 8, 15%). At least one visceral metastasis (liver, lung, kidney, adrenal gland, testis, tumor in the (retro-) peritoneum, pleura, or leptomeningeal carcinomatosis) was found in 23 patients (53%). A low or intermediate tumor burden was found in two patients (4% each). The majority (*n* = 41; 76%) of patients presented with a high tumor burden. Nine patients showed a diffuse bone marrow involvement (16%). More than two thirds of patients (69%) had been previously treated with at least one line of chemotherapy (docetaxel: *n* = 37; cabazitaxel: *n* = 12). Two patients had already undergone two cycles of RLT prior to the current staging more than 1 year before. The median number of systemic treatment lines before RLT was 3.5 (range: 2–6). Serum PSA level was 450 ± 916 ng/ml (range: 0.07–5000) at first cycle of RLT. In total, 139 cycles of RLT were administered with a mean activity of 5.9 ± 0.6 GBq (range: 1.9–6.4).

Disease group classification

Discordant lesions were found in 18 patients. FDG+/PSMA− lesions were seen mostly in the skeleton (*n* = 8) and the liver
(n = 8), two patients showed discordant uptake in lymph nodes, one patient had a discordant prostate lesion, and a one patient had discordant peritoneal tumor in the pelvis. It is possible that patients had more than one “organ system” affected (e.g., bone and liver metastases in one patient as well as bone metastases, liver metastases, and a peritoneal tumor in the pelvis in another patient). In 7 patients, only one FDG+/PSMA− lesion was found, 8 patients had ≤3 discordant lesions, and in 3 patients, ≥4 FDG+/PSMA− lesions were detected. Patients with discordant lesions had a high tumor burden on PSMA ligand PET/CT (n = 15, 83%), and three patients even had a diffuse bone marrow involvement (17%).

Regarding the characteristics of the 18 subjects with one or more FDG+/PSMA− lesions (Table 1), these patients received significantly fewer cycles of RLT (2.0 ± 0.9, range: 1–4) than the other patients (2.9 ± 1.1, range: 1–4; p = 0.005). No difference was found for median Gleason score (8 for both subgroups). In addition, serum PSA levels (543 ± 1258, range: 0.07–5000 ng/ml vs. 404 ± 608, range: 5–2650 ng/ml; p = 0.608), time since diagnosis of prostate cancer (6.3 ± 3, range: 1.8–11.6 years vs. 8.4 ± 6.6, range 1.7–26.3 years, p = 0.209), pre-treatment with docetaxel (72.2% vs. 66.7%; p = 0.685), and ECOG performance status (range: 0–3 vs. 0–2; p = 0.2) did not differ significantly between subgroups.

| Table 1 Patient characteristics of all patients and depending on subgroups | All patients (n = 54) | FDG+/PSMA− (n = 18) | No FDG+/PSMA− (n = 36) |
| --- | --- | --- | --- |
| Age (years) | 71.4 (52–90) | 70.4 (58–82) | 71.9 (52–90) |
| Time since diagnosis of prostate cancer (years) | 7.7 (1.7–26.3) | 6.3 (1.8–11.6) | 8.4 (1.7–26.3) |
| Gleason score | 8 (5–10)* | 8 (7–10)* | 8 (5–10)* |
| PSA (ng/ml) | 450 (0.07–5000) | 543 (0.07–5000) | 404 (5–2650) |
| ECOG | 0–3 | 0–3 | 0–3 |
| Sites of disease: n (patients) | n (patients) | n (patients) | n (patients) |
| Prostate/local | 16 | 4 | 12 |
| Lymph node | 33 | 12 | 21 |
| Bone | 52 | 18 | 34 |
| Liver | 13 | 9 | 4 |
| Lung | 8 | 4 | 4 |
| Other | 9 | 5 | 4 |
| Previous treatment: n (patients) | n (patients) | n (patients) | n (patients) |
| Prostatectomy | 28 | 9 | 19 |
| Radiotherapy to prostate/prostate bed | 31 | 13 | 18 |
| ADT | 54 | 18 | 36 |
| Abiraterone | 44 | 15 | 29 |
| Enzalutamide | 29 | 9 | 20 |
| Docetaxel | 37 | 13 | 24 |
| Cabazitaxel | 12 | 3 | 9 |
| [223Ra]Dichloride | 8 | 3 | 5 |
| Selective internal radiation therapy | 2 | 0 | 2 |
| PSMA RLT | 2 | 1 | 1 |
| Prostvac | 1 | 1 | 0 |
| Estramustin | 1 | 0 | 1 |
| Median lines of treatment before RLT | 3.5 (2–6) | 3.5 (2–6) | 3.5 (2–6) |
| Number of RLT cycles n (patients) | n (patients) | n (patients) | n (patients) |
| 1 cycle | 54 | 18 | 36 |
| 2 cycles | 44 | 12 | 32 |
| 3 cycles | 26 | 5 | 21 |
| 4 cycles | 15 | 1 | 14 |

PSA prostate specific antigen, ECOG performance status according to Eastern Cooperative Oncology Group, ADT androgen deprivation therapy, PSMA RLT prostate-specific membrane antigen-targeted radioligand therapy, other sites of disease: kidney, adrenal gland, testis, tumor in the (retro-)peri toneum, pleura, leptomeningeal carcinomatosis; unknown in *n = 6, ~n = 1, #n = 5.
Prognostic factors

Median OS of all patients \( (n = 54) \) was \( 11 \pm 1.8 \) months (95% CI 7.4–14.6 months). Patients with one or more FDG+/PSMA− lesions \( (n = 18/54) \) had a significantly shorter OS \( (6.0 \pm 0.5 \) months; 95% CI 5.0–7.0 months; \( p < 0.001 \); Fig. 2). A significant difference in OS was also recorded between patients with \( (n = 23/54; \ 7.0 \pm 2.7 \) months, 95% CI 1.6–12.4 months) and without visceral metastases \( (n = 31/54; \ 12.0 \pm 2.1 \) months, 95% CI 7.9–16.1 months; \( p = 0.045 \)) as well as between patients with liver metastases \( (n = 13/54; \ 3.0 \pm 1.1 \) months, 95% CI 0.9–5.1 months) and without liver metastases \( (n = 41/54; \ 13.0 \pm 2.2 \) months, 95% CI 8.7–17.3 months; \( p < 0.001 \)). On univariate cox regression, the ECOG performance status (hazard ratio [HR]: 2.9 95% CI 1.7–5.0; \( p < 0.001 \)) and the extent of metastases on PSMA ligand PET/CT (HR 2.3 95% CI 1.1–4.8; \( p = 0.024 \)) were also significant predictors of OS. Other factors (pretreatment with docetaxel or cabazitaxel, patient’s age, lines of pretreatment, time since initial diagnosis, and Gleason score) were not prognostic for OS \( (p > 0.1) \).

On multivariable analysis between FDG+/PSMA− lesions, visceral metastases, liver metastases, extent of metastases on PSMA ligand PET/CT, ECOG, pretreatment with docetaxel or cabazitaxel, patient’s age, lines of pretreatment, time since initial diagnosis, and Gleason score) were not prognostic for OS \( (p > 0.1) \). Presence of FDG+/PSMA− lesions could be confirmed as a negative prognostic factor: median OS for patients without discrepant FDG+/PSMA− lesions was significantly longer with \( 16 \pm 2.4 \) months as compared to patients with FDG+/PSMA− lesions \( (6.0 \pm 0.5 \) months). This finding is in line with the extended cohort of the LuPSMA Trial with an OS of 13.3 months [15]. Whereas patients with PSMA-negative viable diseases performed particularly poor, our results may indicate that RLT prolongs survival in these patients as compared to subjects being treated with best standard of care. In contrast to our approach in which patients with PSMA-negative metastases were offered PSMA-targeted RLT if this was their last therapeutic option and if the majority of metastases was PSMA-
positive, the LuPSMA trial excluded subjects due to low-PSMA expression (8 of 16 patients) or FDG+/PSMA− findings (8 of 16 patients) [14, 15]. In this cohort, patients with FDG+/PSMA− lesions showed a poor median OS of only 3.9 months under standard of care, which is distinctly shorter than the comparable cohort in our study with 6.0 ± 0.5 months. Furthermore, the authors of the LuPSMA trial discuss that RLT might have improved survival also in this subcohort [16]. To our knowledge, this is the first analysis of patients with dual tracer imaging undergoing RLT without exclusion of patients with heterogeneous tumor lesions. Interestingly, the majority of patients with discordant sites of disease (15/18, 83%) had ≤ 3 FDG+/PSMA− lesions, though the impact of these single lesions was already distinct on OS as shown in a multivariable analysis also considering the extent of metastases on PSMA ligand PET/CT.

As further negative prognostic factors, poorer ECOG status and presence of liver metastases were confirmed on multivariable analysis. This is in line with previous findings demonstrating that the presence of visceral metastases, especially liver metastases, results in poorer survival [20] [21]. ECOG status has also been identified as a prognosticator of OS before [22]. The extent of metastases on PSMA ligand PET/CT was only a significant prognostic marker on univariate analysis

Limitations

This retrospective study suffers from some limitations, the first being the inclusion of a rather small, heterogeneous patient cohort. Second, PET/CT examinations were gained from both [68Ga] and [18F]-labeled PSMA ligands, as both hospitals adapted the radiolabeling procedure during the study period. In order to address potential differences of the PSMA-ligands, a robust visual categorization system with a substantial interrater agreement was developed. Similarly, the impact of different PET/CT scanners used at the two institutions seems negligible. Additionally, the influence of previous cytotoxic treatments can be considered rather small, as these treatments were stopped several weeks before PSMA ligand PET/CT and disease progression was documented.

Finally, the high physiological tracer uptake of the liver when using [18F]PSMA-1007 is a frequent and inherent limitation with possible false-negative hepatic lesions [23].

Conclusion

This study demonstrates a significantly poorer response to PSMA-directed RLT in patients with mCRPC and FDG+/PSMA− lesions, which occurs in about one third of patients. These discordant findings probably indicate a more aggressive biology of disease, and it remains to be elucidated if this patient population still benefits from RLT. Therefore, prospective trials investigating optimal treatment protocols for patients with FDG+/PSMA− lesions, e.g. combination of PSMA-directed RLT and cytotoxic drugs or immunotherapy, are highly warranted.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00259-020-05160-8.

Acknowledgements The authors like to thank Dominikus Stelzer, Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center – University of Freiburg, and Prof. Dr. Samuel Samnich Department of Nuclear Medicine, University Hospital Würzburg, for their support.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability Not applicable.

Compliance with ethical standards

Ethical approval All findings, data acquisition, and processing in this study comply with the ethical standards laid down in the latest Declaration of Helsinki as well as with the statutes of the Ethics Committee of the Universities of Würzburg and Freiburg concerning anonymized retrospective medical studies. There were no fundamental ethical and legal objections to the evaluation of the listed data.

Consent for publication Not applicable.

Competing interests The authors declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol (Toronto, Ont). 2010;17 Suppl 2:S72–9. doi: https://doi.org/10.3747/co.v17i0.718.
2. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48. https://doi.org/10.1056/NEJMoa1209096.
3. Beer TM, Armstrong AJ, Rathkopf DE, Lohi Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. https://doi.org/10.1056/NEJMoa1405095.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. https://doi.org/10.1056/NEJMoa040720.

5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008;26:242–5. https://doi.org/10.1200/jco.2007.12.4008.

6. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer after docetaxel treatment: a randomised open-label trial. Lancet (London, England). 2010;376:1147–54. doi:https://doi.org/10.1016/s0140-6736(10)61389-x.

7. Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 Radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis. Clin Nucl Med. 2018;43:728–34. https://doi.org/10.1097/rlu.00000000000002210.

8. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44. https://doi.org/10.1007/s00259-019-04485-3.

9. Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40:S5–10. doi: .1007/s00259-013-2361-7. Epub 2013 Feb 22.

10. Jadvar H. Is there use for FDG-PET in prostate cancer? Semin Nucl Med. 2016;46:502–6. https://doi.org/10.1053/j.semnuclmed.2016.07.004.

11. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, et al. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013;54:1195–201. https://doi.org/10.2967/jnumed.112.114116.

12. Suman S, Parghane RV, Joshi A, Prabhakar K, Bakshi G, Talole S, et al. Therapeutic efficacy, prognostic variables and clinical outcome of (177)Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-a-vis Gleason score in such cohort. Br J Radiol. 2019;92:20190380. doi: https://doi.org/10.1259/bjr.. Epub 2019 Nov 1.

13. Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Therapeutic advances in medical oncology 2019;11: 1758835919876828. https://doi.org/10.1177/1758835919876828.

14. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19: 825–833. doi: https://doi.org/10.1016/S470-2045(18)30198-0. Epub 2018 May 8.

15. Violet J, Sandhu S, Ivani S, Ferdinando J, Thang SP, Kong G, et al. Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 ([177)Lu] PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. J Nucl Med. 2019;15:236414.

16. Thang SP, Violet J, Sandhu S, Ivani S, Akhurst T, Kong G, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for [(177)Lu]-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2:670–6. https://doi.org/10.1016/j.euo.2018.11.007.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.